Prognostic serum tumor necrosis factor-α in paediatric patients with sepsis

Journal of Infection in Developing Countries

Volumn 3, Issue 6, 2009, Pages 437-441

  Kumar, Surinder ^a   Rizvi, Meher ^a,b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Pediatric; Sepsis; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CHILD HEALTH; CITROBACTER KOSERI; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; ESCHERICHIA COLI; HUMAN; INFANT; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS; SEPTIC SHOCK; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

BACILLI (CLASS); BACTERIA (MICROORGANISMS); CITROBACTER KOSERI; ENTEROBACTER; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; POSIBACTERIA; SERRATIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 73249124960     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.414     Document Type: Article

References (13)

1. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389-393.
2. Parrillo JE, Parker MM, Natanson C (1990) Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 113: 227-242.
3. Bone RC. Pathogenesis of sepsis (1991) Ann Intern Med 115:457-469.
4. th edition,.153-162.New York, Lippincott
5. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Larrere PF (1997) Tumor necrosis receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 277: 1531-8.
6. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273: 934-41.
7. Cohen J, Carlet J (1996) INTERSEPT study group. INTERSEPT: an international multicenter placebo-controlled trial of monoclonal antibody to human TNF-α in patients with sepsis. Crit Care Med 24: 1431-40.
8. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP (1997) The effects of ibuprofen on physiology and survival of patients with sepsis. N Engl J Med 336: 912-8.
9. Kaufman D and Fairchild KD.(2004) Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants. Clin Microbiol Rev 17: 638-680.
10. Fischer CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ (1994) Recombinant human interleukin 1 receptor antagonist inthe treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo controlled trial. JAMA 271: 1836-43.
11. Cohen J and Abraham E (1999) Microbiologic findings and correlation with serum tumor necrosis factor-α in patients with severe sepsis and septic shock. J Infect Dis 180: 116-21.
12. Lemm G, Carlet J, Cohen J (1995) Cytokine levels in patients with the sepsis syndrome treated with a monoclonal antibody to human TNF-α (INTERSEPT trial) [abstract] Clin Intensive Care 6: 68.
13. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD (2004) Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 34: 2173-2182.